Clinical trials
Advanced Solid Tumor (Phase 1) clinical trials
Below are recruiting advanced solid tumor (phase 1) clinical trials, each written for real people, not researchers. We’re tracking 504 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06968572RecruitingPhase 1
New drug for MTAP-deleted solid tumors
This trial tests a new experimental drug (HSK41959) for people with advanced solid tumors that have a specific genetic change (MTAP deletion). The goal is to see if the drug is safe and effective for tumors that no longer respond to standard treatments.
Guiyang, GuizhouAges 18 years+ - NCT07098052RecruitingPhase 1
Study of HDM2020 for advanced solid tumors
This trial is testing a new drug called HDM2020 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if the drug is safe and how well it works.
Guangzhou, GuangdongAges 18–75 - NCT07102004RecruitingPhase 1/Phase 2
Testing a new drug for advanced solid tumors
This trial tests an experimental drug for people with advanced solid tumors, including small cell lung cancer, that have stopped responding to standard treatments. The goal is to find out if the drug is safe and effective.
BeijingAges 18 years+ - NCT07100249RecruitingPhase 1
Study of HDM2012 for advanced solid tumors
This trial tests a new drug, HDM2012, in people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective, especially for gastric and colorectal cancers.
ShanghaiAges 18–75 - NCT07092748RecruitingPhase 1
Testing HS387 for advanced solid tumors
This trial tests a new drug called HS387 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and how well it works.
Hangzhou, ZhejiangAges 18–75 - NCT07087197RecruitingPhase 1
Study of SKB107 for advanced cancer with bone tumors
This trial tests a new drug, SKB107, for people whose advanced cancer has spread to the bones and standard treatments no longer work. The goal is to see if SKB107 can help shrink or slow these bone tumors.
ShanghaiAges 18–75 - NCT07086768RecruitingPhase 1
BSI-082 alone or with T-DXd for advanced solid tumors
This trial tests a new drug, BSI-082, alone or with another drug (T-DXd), for people with advanced solid tumors that no longer respond to standard therapy. It aims to find the best dose and check how well it works.
San Antonio, TexasAges 18 years+ - NCT07083323RecruitingPhase 1/Phase 2
Study of HY05350 for mesothelin-positive advanced solid tumors
This clinical trial tests an experimental drug called HY05350 for people with advanced solid tumors that have a specific protein (mesothelin). It aims to see if the drug is safe and effective for cancers that have not responded to standard treatments.
Beijing, Beijing MunicipalityAges 18–75 - NCT07069062RecruitingPhase 1/Phase 2
Study of HY0001a for Advanced Solid Tumors
This trial tests a new drug, HY0001a, for people with advanced solid tumors that have not responded to standard treatments. The drug targets a protein on some cancer cells, and the study aims to find the right dose and see if it helps shrink tumors.
Beijing, Beijing MunicipalityAges 18–75 - NCT07050459RecruitingPhase 1
Study of SIM0686 for advanced solid tumors
This trial tests a new drug (SIM0686) in people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and how it affects tumors that have a specific protein called FGFR2b on their surface.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07050641RecruitingPhase 1/Phase 2
Study of SCTB39-1 for advanced solid tumors
This trial tests a new drug called SCTB39-1 for people with advanced solid tumors that have not responded to other treatments. The study has two parts: first finding the right dose, then testing how well it works.
BeijingAges 18 years+ - NCT07053904Enrolling by invitationPhase 1
Study of two experimental cancer drugs for advanced solid tumors
This trial tests two new drugs, P1101 and P1801, in people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the combination is safe and effective.
New Taipei CityAges 18 years+ - NCT07046650RecruitingPhase 2
Cisplatin plus gemcitabine for rare tumors after PD-1 therapy
This trial tests a combination of two chemotherapy drugs, cisplatin and gemcitabine, for people with certain rare cancers that no longer respond to a type of immunotherapy called PD-1 inhibitors. The goal is to see how well this treatment works and what side effects it may cause.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07032298RecruitingPhase 1
Testing SSGJ-612 for advanced solid tumors with HER2
This trial tests a new drug called SSGJ-612 for people with advanced solid tumors that have stopped responding to standard treatments. It is specifically for patients whose tumors have a protein called HER2, and it aims to see if the drug can shrink or control the cancer.
Luoyang, HenanAges 18–75 - NCT07016997RecruitingPhase 1
A study of CBA-1535 for advanced solid tumors
This trial tests a new drug, CBA-1535, which is designed to help your immune system attack cancer cells. It is for people with advanced solid tumors who have run out of standard treatment options or cannot tolerate them.
Nagaizumicho, ShizuokaAges 20 years+ - NCT07021534RecruitingPhase 1
CAR-NK and CAR-T cells for cancer with liver spread
This trial tests a new treatment that uses special immune cells (CAR-NK and CAR-T cells) given directly into the liver artery, then through a vein, to fight advanced solid tumors that have spread to the liver. It is for people who have already tried standard treatments and need new options.
Hangzhou, ZhejiangAges 18–75 - NCT06954077RecruitingPhase 1
BL-M09D1 for advanced gastrointestinal and other solid tumors
This trial tests a new drug, BL-M09D1, for people with advanced or metastatic gastrointestinal or other solid tumors that have stopped responding to standard treatments. The goal is to see if the drug can shrink tumors and how safe it is.
Guangzhou, GuangdongAges 18 years+ - NCT06997029RecruitingPhase 1
Study of BMS-986500 for advanced solid tumors
This trial tests a new drug called BMS-986500, alone or with other treatments, for people with advanced solid tumors that cannot be removed by surgery or have spread. It aims to see if the drug is safe and effective.
Birmingham, AlabamaAges 18 years+ - NCT06993870RecruitingPhase 1
First-in-human study of HBT-708 for advanced solid tumors
This trial tests a new drug called HBT-708 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and how the body handles it.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06993844RecruitingPhase 1/Phase 2
Study of ETX-636 for advanced solid tumors with PIK3CA mutation
This trial tests an experimental drug called ETX-636 in people whose cancer has a specific gene change (PIK3CA mutation) and has not responded to at least one prior treatment. The goal is to see if the drug can shrink tumors or stop them from growing.
Newport Beach, CaliforniaAges 18 years+ - NCT07002203RecruitingPhase 1/Phase 2
Personalized cancer vaccine trial for solid tumors
This trial tests a custom-made vaccine designed to train your immune system to fight your specific cancer. It may be an option if you have advanced cancer that stopped responding to treatment or early-stage cancer with a high risk of coming back.
BangkokAges 20 years+ - NCT06987500RecruitingPhase 1/Phase 2
Study of an experimental drug for advanced solid tumors
This trial tests a new drug called XNW29016 for people with advanced cancer that has stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06990698RecruitingPhase 1
Testing FP008 in advanced solid tumors
This trial tests an experimental drug called FP008, which may help the immune system fight advanced solid tumors. It is for people whose cancer has continued to grow despite standard treatments or who cannot tolerate them.
Guangzhou, GuangdongAges 18 years+ - NCT06992687Enrolling by invitationPhase 1/Phase 2
Study of HB0052 for advanced solid tumors
This trial tests a new drug called HB0052 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective for various cancer types.
BeijingAges 18 years+
Hear when a new Advanced Solid Tumor (Phase 1) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced solid tumor (phase 1)?
- Yes. Clin2 currently lists 504 recruiting advanced solid tumor (phase 1) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced solid tumor (phase 1) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced solid tumor (phase 1) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.